As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 52 52 |
3%
3%
|
|
| Gross Profit | 49 49 |
7%
7%
|
|
| EBITDA | -187 -187 |
91%
91%
|
|
| EBIT (Operating Income) EBIT | -189 -189 |
92%
92%
|
|
| Net Profit | -175 -175 |
102%
102%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
| Head office | United States |
| CEO | Jay Duker |
| Employees | 165 |
| Founded | 1987 |
| Website | eyepointpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


